Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Transthyretin-related hereditary amyloidosis Stories

2013-12-02 08:30:17

CARLSBAD, Calif., Dec. 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the ongoing Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a...

2013-07-30 08:33:03

CARLSBAD, Calif., July 30, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the advancement of the ongoing Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by...

2012-11-05 08:32:00

CARLSBAD, Calif., Nov. 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Isis and GlaxoSmithKline (NYSE: GSK) have agreed to amend the clinical development plan and financial terms relating to ISIS-TTR(Rx) to reflect the accelerated development plan for the drug. ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of TTR amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerves...